For example, we previously reported that the phosphorylation state of HER3 could discriminate those patients with HER2+ inflammatory breast cancers who were more likely to respond to lapatinib monotherapy [16]. The gene discussed is ERBB3; the disease is inflammatory breast carcinoma.